Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31563796 | 0.90 | GRM1 (0.61) | GPR119GRM1GRM5LMNAKMT2A | |
| SCHEMBL8614193 | 0.90 | GRM1 (0.60) | GPR119GRM1GRM5LMNATP53 | |
| SCHEMBL28215657 | 0.83 | MIF (0.46) | GPR119GRM1GRM5KMT2A | |
| SCHEMBL23411297 | 0.83 | GRM5 (0.62) | GPR119GRM1GRM5LMNAKMT2A | |
| SCHEMBL20135488 | 0.80 | GPR119 (0.58) | GPR119LMNAKMT2ATP53TDP1 | |
| SCHEMBL20135087 | 0.80 | GPR119 (0.58) | GPR119LMNAKMT2ATP53TDP1 | |
| SCHEMBL31228007 | 0.80 | THRB (0.50) | GPR119 | |
| SCHEMBL20135429 | 0.78 | GPR119 (0.58) | GPR119LMNAKMT2ATP53TDP1 | |
| SCHEMBL12117456 | 0.77 | GPR119 (0.65) | GPR119LMNAKMT2ATP53 | |
| SCHEMBL12614693 | 0.76 | GPR119 (0.56) | GPR119LMNAKMT2ATP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | GPR119 799/4885GRM1 4141/4885GRM5 3744/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | GPR119 997/4885GRM1 3929/4885GRM5 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.